Key Details
India has already built many of the foundations of a globally competitive biotechnology ecosystem and the next phase is to translate these capabilities into economic growth, advanced manufacturing, employment and global technological leadership.
Strategic Focus | Roadmap Proposal |
|---|---|
2035 Vision | Expand India’s bioeconomy from US$195.3 billion (2025) to US$691 billion by 2035, reaching US$2.6 trillion by 2047 |
Development Strategy | Shift from fragmented biotechnology programmes to a BioE3-led national bioeconomy strategy |
Mission-Based Execution | Launch six National BioMissions covering health, agriculture, synthetic biology, marine biotechnology, One Health and biopharmaceuticals |
Growth Enablers | Establish a ₹50,000 crore BioEconomy Growth Fund, biomanufacturing incentives and regulatory reforms |
Future Competitiveness | Build capabilities in AI-enabled biology, BioFoundries, advanced biomanufacturing, indigenous IP and digital biological infrastructure |
India’s Biotechnology Strategy Is Entering an Economic Phase
The NITI Aayog report, Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035, argues that India has moved beyond building scientific capability. Decades of investment have created one of the world’s largest vaccine manufacturing bases, a globally competitive biosimilars industry, a rapidly expanding biotechnology startup ecosystem and strong public research institutions. The next challenge is to convert these strengths into industrial scale, commercial innovation and long-term economic growth.
Rather than viewing biotechnology as a standalone science sector, the report positions the bioeconomy as a strategic pillar of national competitiveness. It projects the sector to grow from US$195.3 billion in 2025 to US$691 billion by 2035, generating high-value employment while strengthening public health, climate resilience, manufacturing and exports.
BioE3 Shifts the Focus from Research to Industrial Scale
The roadmap identifies the BioE3 Policy (Biotechnology for Economy, Environment and Employment) as the framework for this transition. Instead of supporting isolated research programmes, it proposes integrating biotechnology with artificial intelligence, digital biology, advanced manufacturing and industrial policy to accelerate commercialisation.
Its execution strategy centres on six National BioMissions:
GeneIndia for gene and cell therapies
AgriBio 2.0 for climate-resilient agriculture
BioX Foundry for synthetic biology and biomanufacturing
One Health Grid for integrated disease surveillance
Marine Biotechnology for the blue economy
BioPharmaNext for next-generation biologics, vaccines and AI-driven drug discovery
Together, these missions seek to connect research, manufacturing, regulation and market deployment within coordinated long-term programmes.
Financing and Regulation Become the New Growth Enablers
The roadmap argues that scientific capability alone will not deliver global leadership. India’s future competitiveness will increasingly depend on financing, regulation and institutional coordination.
Key recommendations include:
₹50,000 crore BioEconomy Growth Fund (2026–2035) to support scale-up and commercial deployment.
Production-Linked Incentives (PLI) for biomanufacturing.
National BioData Council to govern biological and health data.
BioEconomy Investment & Policy Forum to align public and private investment.
Regulatory sandboxes, faster approval pathways and AI-enabled regulatory systems.
Stronger intellectual property commercialisation through a dedicated Bio-IP framework.
The report cautions that delays in implementing these reforms could leave India dependent on external technologies and supply chains despite its strong scientific base.
What is BioE3?
BioE3 (Biotechnology for Economy, Environment and Employment) is India’s national biotechnology policy framework approved in 2024. It aims to transform biotechnology from a research-led sector into a driver of economic growth by integrating scientific innovation with manufacturing, sustainability, employment generation and industrial competitiveness across healthcare, agriculture, energy and advanced biomanufacturing.
Policy Relevance
Positions biotechnology as a strategic economic and industrial sector rather than a standalone science programme.
Emphasises that manufacturing, commercialisation and financing - not research alone - will determine India’s competitiveness in the global bioeconomy.
Proposes mission-mode implementation through six National BioMissions to better integrate research, industry and public policy.
Calls for coordinated reforms in financing, regulation, AI infrastructure and biomanufacturing to accelerate innovation and scale-up.
Supports India’s long-term objective of building globally competitive biotechnology industries under the Viksit Bharat 2047 vision.
Follow the Full Report Here: Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035